| 非小细胞肺癌免疫检查点抑制剂疗效预测标志物研究进展 |
| |
| 引用本文： | 孔文翠,余宗阳.非小细胞肺癌免疫检查点抑制剂疗效预测标志物研究进展[J].现代肿瘤医学,2020,0(22):4017-4020. |
| |
| 作者姓名： | 孔文翠 余宗阳 |
| |
| 作者单位： | 中国人民解放军联勤保障部队第900医院肿瘤科，福建 福州 350025 |
| |
| 摘 要： | 近年来，免疫靶向治疗成为针对肿瘤微环境干预治疗异军突起的新领域。免疫检查点筛选及免疫检查点抑制剂转化性研究方兴未艾，也逐渐挑战非小细胞肺癌传统治疗。但在泛瘤种、未加选择人群中，仅仅约1/5左右患者可从免疫检查点抑制剂获益。因此，如何筛选免疫检查点抑制剂疗效预测相关标志物，成为当前关注焦点。本文针对预测相关标志物包括PD-L1表达、肿瘤突变负荷、微卫星不稳定、驱动基因状态、DNA损伤修复相关基因突变情况等与免疫检查点抑制剂疗效相关研究进展进行梳理，并结合当前存在的问题提出未来可能的探索方向。
|
| 关 键 词： | 非小细胞肺癌 免疫检查点抑制剂 生物标记物 免疫治疗 |
Review of predictive biomarkers for the immunological checkpoint inhibitors related efficacy in non-small cell lung cancer |
| |
| KONG Wencui,YU Zongyang.Review of predictive biomarkers for the immunological checkpoint inhibitors related efficacy in non-small cell lung cancer[J].Journal of Modern Oncology,2020,0(22):4017-4020. |
| |
| Authors: | KONG Wencui YU Zongyang |
| |
| Affiliation: | Medical Oncology Department,the 900th Hospital of the Joint Support Force of the Chinese People's Liberation Army,Fujian Fuzhou 350025,China. |
| |
| Abstract: | In recent years,immunotargeting therapy has been a new field for the intervention of tumor microenvironment treatment.Checkpoint inhibitors have demonstrated acceptable toxicities,promising clinical responses,durable disease control,and improved survival in the selected patients with advanced non-small cell lung cancer (NSCLC).However，only about twenty percent patients can really benefit from these therapies.How to screen the selected patients? Biomarkers as the highlighted predictive markers have been explored,and potentially help screen the favor patients benefit from checkpoint inhibitors.The review focus on the highlighted biomarkers,including PD-L1 expression,tumor mutation load (TMB),microsatellite instability (MSI),driving gene mutation status,and DNA damage repair related gene mutations in NSCLC patients. |
| |
| Keywords: | non-small cell lung cancer checkpoint inhibitors biomarkers immunotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
